Evidence map›Paper›PMID 23538680›Full record

ReviewWorld journal of gastroenterology2013

Vaccines and recommendations for their use in inflammatory bowel disease.

María Dolores Sánchez-Tembleque, Carmen Corella, Jose L Pérez-Calle

Open access · hybridAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in World journal of gastroenterology, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
1.2field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 14 citations in OpenAlex.

  1. Observational
  2. Article
  3. A guide to prepare patients with inflammatory bowel diseases for anti-TNF-α therapy.Medical science monitor : international medical journal of experimental and clinical research · 2014
    Review
  4. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

María Dolores Sánchez-TemblequeGastroenterology Department, University Hospital of Guadalajara, 19002 Guadalajara, Spain. loladig@hotmail.com
Carmen Corella
Jose L Pérez-Calle
Hospital Universitario de Guadalajara · ES

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The patient with inflammatory bowel disease will be predisposed to numerous infections due their immune status. It is therefore important to understand the immune and serologic status at diagnosis and to put the patient into an adapted vaccination program. This program would be applied differently according to two patient groups: the immunocompromised and the non-immunocompromised. In general, the first group would avoid the use of live-virus vaccines, and in all cases, inflammatory bowel disease treatment would take precedence over vaccine risk. It is important to individualize vaccination schedules according to the type of patient, the treatment used and the disease pattern.In addition, patient with inflammatory bowel disease should be considered for the following vaccines: varicella vaccine, human papilloma virus, influenza, pneumococcal polysaccharide vaccine and hepatitis B vaccine.

Indexed as

Immunocompromised HostVaccinationBacterial InfectionsBacterial VaccinesHumansImmunosuppressive AgentsInflammatory Bowel DiseasesPatient SelectionPractice Guidelines as TopicRisk FactorsTreatment OutcomeViral VaccinesVirus DiseasesBacterial VaccinesImmunosuppressive AgentsViral VaccinesCrohn’s diseaseImmunocompromisedInflammatory bowel diseaseUlcerative colitisVaccines

Identifiers

PMID23538680
PMCPMC3602494
OpenAlexW2151902120

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.